A stabilized version of the anxiolytic peptide Selank with enhanced bioavailability and duration of action.
N-Acetyl Selank is a chemically modified form of the anxiolytic heptapeptide Selank. Like its parent compound, it is a tuftsin analog with anxiolytic (anti-anxiety) and immunomodulatory properties. The N-acetylation and C-terminal amidation modifications increase resistance to enzymatic degradation, improving nasal bioavailability and duration of action.
N-Acetyl Selank retains Selank's unique anxiolytic profile: anxiety reduction without sedation, cognitive impairment, or addiction potential — distinguishing it from benzodiazepines. The modifications may enhance these properties by providing more sustained peptide exposure in the CNS.
The enhanced formulation is particularly popular in nootropic communities where it is used for anxiety management combined with cognitive enhancement — addressing both the emotional and cognitive components of performance.
The parent compound Selank has extensive clinical data from Russian trials demonstrating anxiolytic efficacy comparable to benzodiazepines without their side effects. The acetylated form is expected to provide similar or enhanced effects with improved pharmacokinetics.
Selank's BDNF-enhancing and enkephalin-modulating mechanisms are preserved in the modified form. The extended half-life may provide more consistent anxiolytic effects throughout the day.
📚 Key Reference: PMID: 19086071 (Selank anxiolytic — parent compound)
Expected to be similar to standard Selank — generally well-tolerated. No sedation, no dependence reported with parent compound. Nasal administration is non-invasive. Not FDA-approved. Consult your provider.
NOT FDA-approved. Research use only. Parent compound (Selank) is approved in Russia.